全文获取类型
收费全文 | 1132篇 |
免费 | 67篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 54篇 |
妇产科学 | 43篇 |
基础医学 | 119篇 |
口腔科学 | 2篇 |
临床医学 | 148篇 |
内科学 | 150篇 |
皮肤病学 | 29篇 |
神经病学 | 140篇 |
特种医学 | 84篇 |
外科学 | 122篇 |
综合类 | 14篇 |
一般理论 | 1篇 |
预防医学 | 148篇 |
眼科学 | 8篇 |
药学 | 81篇 |
肿瘤学 | 56篇 |
出版年
2023年 | 10篇 |
2022年 | 10篇 |
2021年 | 30篇 |
2020年 | 18篇 |
2019年 | 48篇 |
2018年 | 30篇 |
2017年 | 30篇 |
2016年 | 22篇 |
2015年 | 32篇 |
2014年 | 40篇 |
2013年 | 56篇 |
2012年 | 117篇 |
2011年 | 101篇 |
2010年 | 56篇 |
2009年 | 38篇 |
2008年 | 73篇 |
2007年 | 97篇 |
2006年 | 68篇 |
2005年 | 57篇 |
2004年 | 58篇 |
2003年 | 49篇 |
2002年 | 30篇 |
2001年 | 6篇 |
2000年 | 8篇 |
1999年 | 8篇 |
1998年 | 5篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 4篇 |
1992年 | 4篇 |
1991年 | 5篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1987年 | 5篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 9篇 |
1983年 | 9篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1976年 | 5篇 |
1975年 | 2篇 |
1974年 | 3篇 |
1973年 | 5篇 |
1971年 | 2篇 |
1969年 | 5篇 |
排序方式: 共有1202条查询结果,搜索用时 15 毫秒
21.
Jinn-Rung Kuo Shih-Shian Lin Janelle Liu Shih-How Chen Chung-Chin Chio Jhi-Joung Wang Jia-Ming Liu 《Biomedical optics express》2015,6(1):23-31
Compared to deep brain electrical stimulation, which has been applied to treating pathological brain diseases, little work has been done on the effect of deep brain light stimulation. A fiber-coupled laser stimulator at 840 nm wavelength and 130 Hz pulse repetition rate is developed in this work for deep brain light stimulation in a rat model. Concentration changes in glutamate and dopamine in the striatum are observed using a microdialysis probe when the subthalamic nucleus (STN) is stimulated at various optical power levels. Experimental results show that light stimulation causes the concentration of glutamate to decrease while that of dopamine is increased. This suggests that deep brain light stimulation of the STN is a promising therapeutic strategy for dopamine-related diseases such as Parkinson’s disease. The stimulator developed for this work is useful for deep brain light stimulation in biomedical research.OCIS codes: (170.5180) Photodynamic therapy, (170.3660) Light propagation in tissues, (170.3890) Medical optics instrumentation, (170.1420) Biology, (170.1610) Clinical applications, (170.0170) Medical optics and biotechnology 相似文献
22.
Do Job Demands of Chinese Manufacturing Employees Predict Positive or Negative Outcomes? A Test of Competing Hypotheses
下载免费PDF全文
![点击此处可从《Stress and health》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Karasek's job demands–control (JDC) model posits that job control can buffer against the harmful effects of demands experienced by employees. A large volume of JDC research has obtained support for the main effects of demands and control, but not the interactive effects. Recent research on the challenge–hindrance stressors framework, however, found that work stressors may not always be deleterious, suggesting alternative hypotheses about the effects of demands and control. The present study therefore examined competing hypotheses concerning the effects of job demands on occupational health outcomes. Using a sample of 316 employees in a Chinese manufacturing company, we found that, consistent with the challenge–hindrance framework, production demands were challenge stressors associated with favourable outcomes (i.e. job satisfaction and psychological well‐being). In addition, results showed that the interactive role of job control depended on the nature of outcome variables. Future recommendations and implications of findings are discussed. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
23.
24.
Perkins JB Shapiro JF Bookout RN Yee GC Anasetti C Janssen WE Fernandez HF 《American journal of hematology》2012,87(7):673-677
We performed a retrospective analysis to evaluate clinical and economic outcomes in patients receiving remobilization therapy after primary mobilization failure. Our primary endpoint was to compare filgrastim plus plerixafor to other regimens in their ability to collect a target cell dose of at least 2 million CD34+ cells/kg (cumulative). Of 96 consecutive patients who failed their primary mobilization therapy and in whom a second mobilization was attempted, remobilization consisted of filgrastim plus plerixafor (n = 38), filgrastim with or without sargramostim (n = 43), or chemotherapy plus filgrastim (n = 15), 84% of filgrastim/plerixafor patients were able to collect at least 2 million CD34+ cells/kg from both mobilizations, compared to 60% of patients mobilized with chemotherapy/filgrastim and 79% of the filgrastim ± sargramostim patients (P = 0.17). However, when combined with cells collected from the first mobilization, 53% of filgrastim/plerixafor patients reached the target of 2 million CD34+ cells in one apheresis, compared to 20% of those receiving chemotherapy/filgrastim and 28% of those receiving filgrastim ± sargramostim (P = 0.02). Resource utilization, mobilization drug costs, clinical care costs, and total costs were significantly different. We conclude that while filgrastim/plerixafor is the most efficient remobilization strategy, those clinical benefits may not translate into lower cost, especially when multiple days of plerixafor administration are required. 相似文献
25.
26.
Differences in Selected HIV Care Continuum Outcomes Among People Residing in Rural,Urban, and Metropolitan Areas—28 US Jurisdictions
下载免费PDF全文
![点击此处可从《The Journal of rural health》网站下载免费的PDF全文](/ch/ext_images/free.gif)
John A. Nelson PhD Anna Kinder MS Anna Satcher Johnson MPH H. Irene Hall PhD Xiaohong Hu MS Donna Sweet MD Alyssa Guido MPH Harold Katner MD Jennifer Janelle MD Maribel Gonzalez MSN Natalia Martínez Paz MA MPA Charlotte Ledonne BSN MA Jason Henry Theresa Bramel MHS Jeanne Harris BSN MBA 《The Journal of rural health》2018,34(1):63-70
Purpose
The HIV care continuum is used to monitor success in HIV diagnosis and treatment among persons living with HIV in the United States. Significant differences exist along the HIV care continuum between subpopulations of people living with HIV; however, differences that may exist between residents of rural and nonrural areas have not been reported.Methods
We analyzed the Centers for Disease Control and Prevention's National HIV Surveillance System data on adults and adolescents (≥13 years) with HIV diagnosed in 28 jurisdictions with complete reporting of HIV‐related lab results. Lab data were used to assess linkage to care (≥1 CD4 or viral load test ≤3 months of diagnosis), retention in care (≥2 CD4 and/or viral load tests ≥3 months apart), and viral suppression (viral load <200 copies/mL) among persons living with HIV. Residence at diagnosis was grouped into rural (<50,000 population), urban (50,000‐499,999 population), and metropolitan (≥500,000 population) categories for statistical comparison. Prevalence ratios and 95% CI were calculated to assess significant differences in linkage, retention, and viral suppression.Findings
Although greater linkage to care was found for rural residents (84.3%) compared to urban residents (83.3%) and metropolitan residents (81.9%), significantly lower levels of retention in care and viral suppression were found for residents of rural (46.2% and 50.0%, respectively) and urban (50.2% and 47.2%) areas compared to residents of metropolitan areas (54.5% and 50.8%).Conclusions
Interventions are needed to increase retention in care and viral suppression among people with HIV in nonmetropolitan areas of the United States. 相似文献27.
28.
Li Li Sandeep Kumar Patrick M. Buck Christopher Burns Janelle Lavoie Satish K. Singh Nicholas W. Warne Pilarin Nichols Nicholas Luksha Davin Boardman 《Pharmaceutical research》2014,31(11):3161-3178
Purpose
Early identification of monoclonal antibody candidates whose development, as high concentration (≥100 mg/mL) drug products, could prove challenging, due to high viscosity, can help define strategies for candidate engineering and selection.Methods
Concentration dependent viscosities of 11 proprietary mAbs were measured. Sequence and structural features of the variable (Fv) regions were analyzed to understand viscosity behavior of the mAbs. Coarse-grained molecular simulations of two problematic mAbs were compared with that of a well behaved mAb.Results
Net charge, ξ-potential and pI of Fv regions were found to correlate with viscosities of highly concentrated antibody solutions. Negative net charges on the Fv regions of two mAbs with poor viscosity behaviors facilitate attractive self-associations, causing them to diffuse slower than a well-behaved mAb with positive net charge on its Fv region. An empirically derived equation that connects aggregation propensity and pI of the Fv region with high concentration viscosity of the whole mAb was developed.Conclusions
An Fv region-based qualitative screening profile was devised to flag mAb candidates whose development, as high concentration drug products, could prove challenging. This screen can facilitate developability risk assessment and mitigation strategies for antibody based therapeutics via rapid high throughput material-free screening. 相似文献29.
30.
Frew AJ Lindemann RK Martin BP Clarke CJ Sharkey J Anthony DA Banks KM Haynes NM Gangatirkar P Stanley K Bolden JE Takeda K Yagita H Secrist JP Smyth MJ Johnstone RW 《Proceedings of the National Academy of Sciences of the United States of America》2008,105(32):11317-11322
Histone deacetylase inhibitors (HDACi) and agents such as recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic anti-TRAIL receptor (TRAIL-R) antibodies are anticancer agents that have shown promise in preclinical settings and in early phase clinical trials as monotherapies. Although HDACi and activators of the TRAIL pathway have different molecular targets and mechanisms of action, they share the ability to induce tumor cell-selective apoptosis. The ability of HDACi to induce expression of TRAIL-R death receptors 4 and 5 (DR4/DR5), and induce tumor cell death via the intrinsic apoptotic pathway provides a molecular rationale to combine these agents with activators of the TRAIL pathway that activate the alternative (death receptor) apoptotic pathway. Herein, we demonstrate that the HDACi vorinostat synergizes with the mouse DR5-specific monoclonal antibody MD5-1 to induce rapid and robust tumor cell apoptosis in vitro and in vivo. Importantly, using a preclinical mouse breast cancer model, we show that the combination of vorinostat and MD5-1 is safe and induces regression of established tumors, whereas single agent treatment had little or no effect. Functional analyses revealed that rather than mediating enhanced tumor cell apoptosis via the simultaneous activation of the intrinsic and extrinsic apoptotic pathways, vorinostat augmented MD5-1-induced apoptosis concomitant with down-regulation of the intracellular apoptosis inhibitor cellular-FLIP (c-FLIP). These data demonstrate that combination therapies involving HDACi and activators of the TRAIL pathway can be efficacious for the treatment of cancer in experimental mouse models. 相似文献